WO2001083700A2 - Oral gram(+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal - Google Patents

Oral gram(+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal Download PDF

Info

Publication number
WO2001083700A2
WO2001083700A2 PCT/US2001/014080 US0114080W WO0183700A2 WO 2001083700 A2 WO2001083700 A2 WO 2001083700A2 US 0114080 W US0114080 W US 0114080W WO 0183700 A2 WO0183700 A2 WO 0183700A2
Authority
WO
WIPO (PCT)
Prior art keywords
bacteria
gram
glutamine composition
composition
glutamine
Prior art date
Application number
PCT/US2001/014080
Other languages
French (fr)
Other versions
WO2001083700A3 (en
Inventor
Pinaki Panigrahi
Original Assignee
University Of Maryland, Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Maryland, Baltimore filed Critical University Of Maryland, Baltimore
Priority to EP01937205A priority Critical patent/EP1292189A4/en
Priority to AU2001262966A priority patent/AU2001262966A1/en
Priority to US10/275,171 priority patent/US20040096427A1/en
Priority to CA002407724A priority patent/CA2407724A1/en
Publication of WO2001083700A2 publication Critical patent/WO2001083700A2/en
Publication of WO2001083700A3 publication Critical patent/WO2001083700A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A composition and method for treating and preventing gastro-intestinal injury are disclosed. The composition includes a combination of Gram (+) bacteria, in particular ∫i⊃Lactobacillus∫/i⊃ and/or ∫i⊃Bifidobacteria∫/i⊃, and glutamine. The method involves orally or naso-gastrically administering a composition containing Gram (+) bacteria, in particular ∫i⊃Lactobacillus∫/i⊃, and glutamine. The composition, which blocks translocation of bacterial agents such as Gram (-) bacteria, other infectious agents, toxins, chemicals and injurious substances, may be used in the prevention and treatment of symptoms and/or disease that result from translocation of Gram (-) bacteria, including inflammation in the gastro-intestinal tract, Neonatal Necrotizing Enterocolitis (NEC) and bacterial sepsis.

Claims

WHAT IS CLAIMED IS:
1. A method of preventing gastro-intestinal dysfunction comprising orally administering a Gram (+) bacteria and glutamine composition.
2. The method of claim 1, wherein said Gram (+) bacteria and
glutamine composition protects tissues along the gastro-intestinal tract by
blocking bacteria or other agent adherence to mucosal layers and by blocking bacteria or other agent translocation across said mucosal layers.
3. The method of claim 2, wherein translocation of agents selected
from the group consisting of infectious agents, toxins, chemicals, and injurious
substances is blocked.
4. The method of claim 1, further comprising optimizing mucosal
defense due to an intraluminal/apical presence ofthe Gram (+) bacteria and
glutamine composition.
5. The method of claim 1 wherein the administering comprises
administering to individuals selected from a group consisting of pre-term infants,
full-term infants, children and adults.
6. The method of claim 1 wherein the administering comprises
administering the Gram (+) bacteria and glutamine composition as a powder.
7. The method of claim 1, wherein the administering comprises
administering the Gram (+) bacteria and glutamine composition mixed in a fluid.
8. The method of claim 1 , wherein the administering comprises
administering the Gram (+) bacteria and glutamine composition as capsules.
-20-
9. The method of claim 8, wherein the capsules are acid-resistant
slow-release micro-capsules.
10. The method of claim 8, wherein the capsules are coated acid-
resistant slow-release capsules.
11. The method of claim 1 , further comprising administering other
drugs for treatment of gastro-intestinal ailments with the Gram (+) bacteria and
glutamine composition.
12. The method of claim 2, wherein the blocking bacterial
translocation comprises blocking Gram (-) bacteria..
13. A method of preventing gastro-intestinal dysfunction characterized
by infection or inflamation comprising orally administering a Gram (+) bacteria
and glutamine composition and allowing the Gram (+) bacteria and glutamine
composition to coat gastro-intestinal mucosa.
14. The method of Claim 13, further comprising preventing conditions
selected from the group consisting of NEC and bacterial sepsis.
15. A Gram (+) bacteria and glutamine composition.
16. The Gram (+) bacteria and glutamine composition of Claim 15,
said Gram (+) bacteria and glutamine composition blocks epithelial cell bacterial
adherence and translocation.
17. A vaccine prepared using the Gram (+) bacteria and glutamine
composition of Claim 15.
-21-
PCT/US2001/014080 2000-05-03 2001-05-03 Oral gram(+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal WO2001083700A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP01937205A EP1292189A4 (en) 2000-05-03 2001-05-03 Oral gram (+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal
AU2001262966A AU2001262966A1 (en) 2000-05-03 2001-05-03 Oral gram (+) bacteria and glutamine composition for prevention and/or treatmentof gastro-intestinal dysfunctions including inflammation in the gastro-intestin al tract, neonatal necrotizing enterocolitis (nec) and bacterial sepsis
US10/275,171 US20040096427A1 (en) 2001-05-03 2001-05-03 Oral gram(+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal dysfunctions including inflammation in the gastro-intestinal tract, neonatal necrotizing enterocolitis (nec) and bacterial sepsis
CA002407724A CA2407724A1 (en) 2000-05-03 2001-05-03 Oral gram(+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20140800P 2000-05-03 2000-05-03
US60/201,408 2000-05-03

Publications (2)

Publication Number Publication Date
WO2001083700A2 true WO2001083700A2 (en) 2001-11-08
WO2001083700A3 WO2001083700A3 (en) 2002-02-07

Family

ID=22745700

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/014080 WO2001083700A2 (en) 2000-05-03 2001-05-03 Oral gram(+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal

Country Status (4)

Country Link
EP (1) EP1292189A4 (en)
AU (1) AU2001262966A1 (en)
CA (1) CA2407724A1 (en)
WO (1) WO2001083700A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2378134A (en) * 2001-06-13 2003-02-05 Mars Uk Ltd Glutamine containing health food
WO2004067731A1 (en) 2003-01-31 2004-08-12 Probi Ab New strains of bifidobacterium having the ability to produce glutamine

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707353A (en) * 1995-12-21 1998-01-13 Abbott Laboratories Oral administration of beneficial agents
US5755688A (en) * 1995-01-13 1998-05-26 Abbott Laboratories Alteration of nutritional product during enteral tube feeding
US5981590A (en) * 1997-03-17 1999-11-09 Probiotix, Inc. Oral glutamine in the prevention of neonatal necrotizing enterocolitis and other gastrointestinal mucosal damage
US6007808A (en) * 1995-06-23 1999-12-28 Dibra S.P.A. Pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders
US6132710A (en) * 1997-03-17 2000-10-17 Probiotix, Inc. Preventing/treating neonatal NEC by administering lactobacillus salivarius and lactobacillus plantarum or a combination thereof
US6156355A (en) * 1998-11-02 2000-12-05 Star-Kist Foods, Inc. Breed-specific canine food formulations
US6203797B1 (en) * 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
US6262019B1 (en) * 1998-04-30 2001-07-17 Vit-Immune, L. C. Method of treatment of glutathione deficient mammals

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5755688A (en) * 1995-01-13 1998-05-26 Abbott Laboratories Alteration of nutritional product during enteral tube feeding
US6007808A (en) * 1995-06-23 1999-12-28 Dibra S.P.A. Pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders
US5707353A (en) * 1995-12-21 1998-01-13 Abbott Laboratories Oral administration of beneficial agents
US5981590A (en) * 1997-03-17 1999-11-09 Probiotix, Inc. Oral glutamine in the prevention of neonatal necrotizing enterocolitis and other gastrointestinal mucosal damage
US6132710A (en) * 1997-03-17 2000-10-17 Probiotix, Inc. Preventing/treating neonatal NEC by administering lactobacillus salivarius and lactobacillus plantarum or a combination thereof
US6203797B1 (en) * 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
US6262019B1 (en) * 1998-04-30 2001-07-17 Vit-Immune, L. C. Method of treatment of glutathione deficient mammals
US6156355A (en) * 1998-11-02 2000-12-05 Star-Kist Foods, Inc. Breed-specific canine food formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1292189A2 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2378134A (en) * 2001-06-13 2003-02-05 Mars Uk Ltd Glutamine containing health food
GB2378134B (en) * 2001-06-13 2005-12-14 Mars Uk Ltd Health food
WO2004067731A1 (en) 2003-01-31 2004-08-12 Probi Ab New strains of bifidobacterium having the ability to produce glutamine
US7947482B2 (en) 2003-01-31 2011-05-24 Probi Ab Strains of bifidobacterium having the ability to produce glutamine

Also Published As

Publication number Publication date
EP1292189A4 (en) 2003-08-13
AU2001262966A1 (en) 2001-11-12
WO2001083700A3 (en) 2002-02-07
EP1292189A2 (en) 2003-03-19
CA2407724A1 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
Kruis Antibiotics and probiotics in inflammatory bowel disease
US8853269B2 (en) Composition and method for treating infections and promoting intestinal health
ES2326933T3 (en) ENTERIC FORMULATIONS OF COMPOSITIONS OF ANTIDIARARIC PROANTOCIANIDINE POLYMERS.
US8003118B2 (en) Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
AU2001244611B2 (en) Preparations for preventing bile acid diarrhea
US5631022A (en) Picosulfate dosage form
JP3425441B2 (en) Treatment of non-inflammatory and non-infectious bowel disorders
Turck et al. Comparison of racecadotril and loperamide in children with acute diarrhoea
US20120053239A1 (en) Treatment for intestinal gas, bloating, microscopic colitis, inflammatory bowel disease and traveler's diarrhea using colloidal bismuth subcitrate
JP2009537547A (en) Biological therapeutic compositions and uses thereof
JPH07505901A (en) Synergistic combination of a substance that inhibits gastric acid secretion and an acid-degradable antibiotic
IE921193A1 (en) Pharmaceutical composition
CN109893516A (en) For treating the pharmaceutical composition of helicobacter pylori
WO2018136490A1 (en) Compositions and methods for common colds
JP2005501862A (en) One-time dosage of azithromycin
US20060210483A1 (en) Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
JPS62145022A (en) Drug for food poisoning
EP1292189A2 (en) Oral gram (+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal
JP4933000B2 (en) Anti-Helicobacter pylori
Nord Effect of quinolones on the human intestinal microflora
CN111184867A (en) Chemical medicine composition for treating helicobacter pylori infection
CN1951386A (en) Medicinal combinations composed by meropenem with three kinds of sputum removing medicament respectively
WO2007067663A1 (en) Use of adsorbent carbon microspheres for the treatment of irritable bowel syndrome
Shanks et al. Comparison of oral erythromycin ethylsuccinate and clavulanate-potentiated amoxicillin in the treatment of acute respiratory tract infections
CN1242988A (en) Medicine composition for treating spirobacillus infection of pylorus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2407724

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001937205

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001937205

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10275171

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2001937205

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: JP